PPARG and COVID-19: Second, the use of PPARγ agonists may be highly appropriate in this context, since (a) they can actually be potently anti-inflammatory, (b) can reduce hyperglycemia (common in critical COVID-19 patients), (c) can modulate ACE2 expression, (d) reduce LPS levels in circulation, and (e) improve the adipogenic phenotype in lipofibroblasts, thus reducing their trans-differentiation into myofibroblasts.